Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors
| Autor: | Hakim Mahammedi, P. Chollet, A.F. Dillies, Emilie Thivat, Marie-Ange Mouret-Reynier, Fabrice Kwiatkowski, A. Bellière, I. van Praagh, Régine Chevrier, Xavier Durando |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Administration Oral Breast Neoplasms Pilot Projects Deoxycytidine Medication Adherence Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Effective treatment Humans Medication Errors Dosing Prospective Studies Capecitabine Aged Aged 80 and over Patient Nonadherence business.industry Aromatase Inhibitors Cancer Lapatinib General Medicine Middle Aged medicine.disease Prognosis stomatognathic diseases Oncology Physical therapy Quinazolines Patient Compliance Female Fluorouracil business Colorectal Neoplasms |
| Zdroj: | Oncology. 84(2) |
| ISSN: | 1423-0232 |
| Popis: | Purpose: Patient nonadherence to oral antineoplastic therapy is a well-recognized barrier to effective treatment. In order to identify patients who may need additional support to become adherent, it is important to have a useful tool that takes into account all the parameters of adherence to prescription. The aim of this prospective study was to evaluate adherence of oral antineoplastic agents and to investigate two calculation methods of adherence score. Patients and Methods: Twenty-nine cancer patients were enrolled in this study. Fourteen were treated by capecitabine and 15 patients by aromatase inhibitors. Adherence was measured using a medication event monitoring system and adherence score was calculated by a usual method and a composite adherence score that takes into account missed doses and also intake interval errors (between 2 doses and between meals). Results: Across the 6-month evaluation period, average adherence was 95% with the standard calculation (capecitabine group: 89%; aromatase inhibitor group: 99%) versus 83% with the composite index (capecitabine group: 62%; aromatase inhibitor group: 99%) (p = 0.030). The composite calculation permits to highlight more nonadherent patients (29.6 vs. 7.4%), particularly in the capecitabine group (73 vs. 18%, p = 0.001). We report 2 cases identified as nonadherent with composite adherence rate. Conclusion: The composite adherence score permits to better evaluate adherence to prescription and to identify barriers to adherence and persistence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|